Continuing Education Activity

This comprehensive course explores the facets of the viral disease poliomyelitis, encompassing a spectrum from self-limiting illness to acute flaccid paralysis. Vital aspects such as diagnosis, prevention, treatment, and associated complications, primarily focusing on the pivotal role of vaccination as a key preventive measure, are covered. Participants learn about the global impact of polio, examining its historical context and the remarkable strides achieved through vaccination efforts, nearly eradicating the disease. The course sheds light on the ongoing relevance of polio in regions with inadequate sanitation, guiding healthcare providers in recognizing and managing cases, especially in endemic areas.

A key highlight of this course lies in its multidisciplinary approach. By engaging in this activity, healthcare professionals will collaboratively enhance their competence. Interprofessional teams are crucial in navigating the complexities of poliomyelitis, contributing to effective patient care, and bolstering public health efforts. From understanding vaccination strategies to recognizing polio-like illnesses and differentiating them from other viral infections, participants will gain a holistic perspective that transcends individual disciplines.

Objectives:

• Identify early clinical manifestations of poliomyelitis, recognizing the varied presentations from self-limiting illness to acute flaccid paralysis.
• Screen populations at risk for polio, with a focus on regions with poor sanitation, to facilitate early detection and targeted preventive measures.
• Implement vaccination strategies effectively, emphasizing the critical role of immunization as primary prevention against poliomyelitis.
• Determine the importance of improving care coordination amongst the interprofessional team to improve outcomes for patients with poliomyelitis and postpolio syndrome.

Introduction

Poliomyelitis, or polio, is an infectious disease transmitted by fecal-oral contamination with lymphatic replication. Before global health efforts, polio caused widespread morbidity and mortality in children during multiple epidemics between 1900 and 1950. Due to worldwide vaccination efforts in the 1980s, polio has been almost completely eradicated.[1][2] This disease primarily impacts developing countries with poor sanitation. Healthcare providers in endemic regions or those caring for patients with recent travel to endemic regions should have a high suspicion of polio in patients with viral prodrome symptoms and new-onset paralysis. Consider early serologic testing because this disease can cause static flaccid paralysis in a minority of those infected if undetected. Postpolio syndrome (PPS) is a progressive syndrome of muscular weakness that may occur later in life. In light of the recent increase in poliolike illnesses in the US, it is important to differentiate between poliomyelitis and other viruses such as enterovirus-D68.[3]

Etiology

Poliovirus, the virus causing acute polio and postpolio syndrome, is a member of the Picornaviridae family and belongs to the Enterovirus C species. There are 3 serotypes of wild poliovirus: types 1, 2, and 3.[4] Wild poliovirus 1 was the primary cause of most of the world’s paralytic polio cases until vaccines became widespread. Wild types 2 and 3 are considered eradicated as of 2015.[1]

There are cases of paralytic poliomyelitis due to a loss of viral attenuation in the oral polio vaccine (OPV), known as vaccine-associated paralytic poliovirus (VAPP). VAPP is extremely rare, occurring approximately 3.8 times per million cases in countries using the oral poliovirus vaccine. VAPP is associated with serotype 3 and is most common in patients with immunodeficiency. There is a theory that circulating maternal antibodies and the timing of the first OPV dose affect the risk of developing VAPP.[5]

Another potential paralytic poliomyelitis is vaccine-derived; this is caused by mutations of the attenuated virus within the OPV that can lead to increased virulence and allow for naturally selective proliferation in populations with low herd immunity. Due to this risk, a worldwide movement has been made to increase the use of inactivated polio vaccine (IPV) and remove attenuated type 2 polio within the OPV formulation to create a bivalent OPV (containing only types 1 and 3).[6] In the United States, IPV is the only vaccine available, with the CDC recommending a 4-dose schedule (see Treatment/Management section).

Epidemiology

Before global health initiatives, nearly 1 in 200 patients with poliomyelitis developed permanent paralysis. In 1988, 350,000 cases of endemic poliomyelitis spread across 125 countries.[7] That same year, the World Health Assembly set goals for completely eradicating wild-type polio. Since then, type 1 has been the only circulating wild type and is endemic only to Pakistan and Afghanistan, and sporadic outbreaks continue to occur. In late 2021 into early 2022, wild-type polio type 1 caused paralytic polio in 9 patients in Southeastern Africa. The outbreak was related to a virus traced back to Pakistan.[8] Recent cases of type 2 polioviruses derived from oral vaccines are also increasing in sub-Saharan Africa and Asia.[1] Some barriers to complete eradication include poor program compliance and access to healthcare in remote endemic areas. Routine childhood vaccination has been successful against the spread of the disease globally, with a 99% reduction in cases from the earlier stated 350,000 in 1988 to just 33 in 2018.[7]

Pathophysiology

Poliovirus primarily spreads via fecal-oral contamination, but oral-oral spread is also possible. Primary infection can lead to viral replication in oropharyngeal and gastrointestinal lymphatic tissues. Maximum viral excretion begins 2 to 3 days before symptoms start and continues for an additional week.[9] In up to 95% of cases, infections are non-paralytic, presenting as a flu-like illness. In approximately 5% of cases, pure motor paralysis can occur.[10] The spread of the virus to the central nervous system is poorly understood. If this spread occurs, the virus may cause anterior horn neuronal death, resulting in a physical exam consistent with intact sensation and pure motor deficits.[11]

Histopathology

Enlarged motor neurons are characteristic but not pathognomonic of poliovirus. The original innervating neurons are destroyed in the muscle fibers affected by acute poliomyelitis. Neighboring neurons attempt to reinnervate the denervated tissue; this leaves the surrounding motor units innervating more muscle fibers than intended, enlarging the affected neuron, and is suspected to be part of the fatigue associated with postpolio syndrome later in life.[12]

History and Physical

During patient evaluation, a pure motor deficit (sensation intact) alongside a viral prodrome is suggestive of paralytic poliomyelitis. Seventy-five percent of infections are subclinical. Clinically, the prodrome may consist of headaches, myalgias, fatigue, nausea, neck stiffness, or pharyngitis. Up to 95% of poliovirus infections present with this constellation of symptoms and remain non-paralytic. Five percent may develop aseptic meningitis. In infections that progress into the spinal cord, severe muscle spasms with myalgias typically present before an asymmetrical flaccid paralysis. The paralysis tends to have a lower limb predominance. Acute flaccid myelitis with viral prodrome can also be caused by other viral infections (see Differential Diagnosis section). Most other enterovirus-related acute flaccid myelitis conditions have an upper extremity predilection.[11]

Poliomyelitis can present in stages, such as the acute stage, recovery stage, and residual paralysis stage. The acute stage is marked by symptoms such as fever, neck stiffness, profound muscular weakness, paraparesis, and autonomic dysfunction. In the convalescent or recovery stage, the acute features disappear, and the recovery of paralyzed muscles begins. This stage can last up to 2 years, with maximal improvement occurring in 6 months. In the last stage, the patient is left with residual paralysis, imbalance of muscle power, and poor posture. Sixty percent of patients have some form of residual deficit. 

Evaluation

Clinicians should have a high suspicion of viral meningitis when acute flaccid paralysis is present. Testing should include blood, cerebral spinal fluid, respiratory, stool viral cultures, and polymerase chain reaction to detect poliovirus or other viruses in the differential diagnosis. Electromyograms and brain/spinal cord magnetic resonance imaging should be obtained to rule out other pathologies. There are no definitive biomarkers widely accepted regarding postpolio syndrome; diagnosis is made by exclusion. There is currently early research on potential biomarkers of postpolio syndrome in the cerebral spinal fluid using polymerase chain reaction.[13]

Treatment / Management

Supportive care is the mainstay of treatment, as no approved antiviral poliomyelitis medications exist. In patients affected by paralytic polio, most (60%) do not regain full strength. The more severe the acute phase of the disease is, the greater the likelihood of residual deficits and the development of postpolio syndrome in the future.[14]

Polio immunity is accomplished by administering inactivated polio vaccine (IPV) or live-attenuated oral polio vaccine (OPV, Sabin). In developing countries, the OPV is still used primarily because of cost and ease of administration. However, due to the increased possibility of VAPP with its use, IPV is preferred in most vaccination schedules. The OPV formulation is changing to remove type 2 to reduce the chance of strain mutations, as type 2 is the most common strain of VAPP. Type 2 is being phased out because its wild-type has been eradicated as of 1999, yet it continues to cause outbreaks of VAPP in countries previously completely free of polio.[5] In the United States, IPV is the only vaccine available. Children typically receive 4 doses of IPV at 2 and 4 months, then between 6 and 18 months, followed by a booster between 4 and 6 years of age. This vaccine schedule confers greater than 95% efficacy.[15] A single lifetime IPV booster is recommended for adults who have completed the primary series but may be traveling to areas with circulating viruses.[16]

The release of joint contractures is also an important management step. Many surgical interventions can be considered to reestablish balance in the muscles around the joint to prevent deformities. Surgical management aims to get the patient walking and correct factors that will lead to deformity with age.

In the acute stage, treatment involves general supportive measures for fever and irritation, preventing respiratory tract infections, and managing respiratory paralysis. The paralyzed legs are supported by splints to relieve pain and spasms; splints also play an imperative role in the prevention of the development of deformities.

In the convalescent stage, the goal should be to achieve an acceptable physical status for the patients to be integrated into their communities. Nonfatiguing exercise programs are the most appropriate to deal with muscle overuse weakness. Orthoses are helpful in the conservative and definitive treatment of many deformities and are available for all body parts.

Differential Diagnosis

Other viruses can cause acute flaccid paralysis, including enterovirus A71, enterovirus D68, and coxsackievirus A.[3] Many healthcare professionals have advocated for continual surveillance of novel enteroviruses that may be associated with paralysis.[17] Other viruses that may cause similarly presenting signs and symptoms include the West Nile virus, varicella-zoster virus, Japanese encephalitis virus, and rabies virus. Syndromes, such as Guillain-Barré, should also be ruled out.[18][19] 

Noninfectious considerations include spinal cord infarctions, acquired axonal neuropathies, myasthenia gravis, Lambert-Eaton myasthenic syndrome, or rhabdomyolysis. Clinical clues such as injury to an affected limb compared to prodromal illness will help to differentiate between diagnoses.

Prognosis

The presentation of polio is variable, ranging from viral symptoms without paralysis to quadriplegia and even respiratory failure. Patients with polio who present with only viral prodromes are likely to see complete resolution of symptoms. For those who experience acute paralysis, the degree of paralysis often remains static. Approximately 30% to 40% of patients with polio will develop postpolio syndrome decades after the primary infection. This multifactorial progression depends on factors including severity of acute paralysis, age of onset, and even socioeconomic status.[14][20][21]

Complications

The most significant complications of polio infection include paralysis with bulbar involvement, fatal respiratory and cardiovascular collapse, and postpolio syndrome; postpolio syndrome is characterized by new-onset or progressive muscle weakness in a patient previously diagnosed with poliomyelitis.[14][20] There is an estimation that up to 40% of the 15 to 20 million known polio survivors worldwide develop some form of postpolio syndrome. The classic symptom is new or progressive muscle weakness decades after the acute infection. Other symptoms include myalgias, respiratory distress, joint pain, atrophy, dysphagia, and generalized fatigue.[22] The exact pathophysiology of PPS is unknown; this condition is believed to result from the overuse of remaining motor units, inflammatory changes in the central nervous system, or deteriorating neuromuscular junctions.[23] Complications of this syndrome include respiratory failure, fractures, or failure to thrive.

Postoperative and Rehabilitation Care

Rehabilitation and a strong interdisciplinary team are crucial, as 60% to 80% of patients previously diagnosed with polio reported falling at least once in the past year.[21] Postpolio syndrome treatment priorities: Tailored physical therapy, aquatic therapy, endurance training, and pain control. Fitted orthoses can mitigate gait disturbances. Potential orthopedic surgery may be warranted to correct deformities and muscle imbalances.[23] Tricyclic antidepressants are effective against fatigue associated with postpolio syndrome. There is high variability in the postpolio syndrome presentation, and each must be carefully considered when beginning treatment plans.

Deterrence and Patient Education

Patients must be educated on preventing transmission with proper hygiene and prevention through vaccination efforts. As more communities worldwide oppose vaccinations, informing the public about the potentially deadly and disabling side effects of not receiving the polio vaccine can be helpful. The Global Polio Eradication Initiative partners with the World Health Organization, US Centers for Disease Control (CDC), Rotary International, United Nations Children’s Fund, and the Bill & Melinda Gates Foundation to work for a polio-free world. They have laid out a Polio Endgame Strategy with the following key components:

Routine Immunization

• Goal of greater than 80% vaccination of all children in the first year of life
• At least 3 doses of OPV (or IPV per current CDC recommendations) as part of the national immunization schedule

Supplementary Immunization

• Mass immunization campaigns are known as National Immunization Days
• 2 rounds, 1 month apart from each other
• Immunize all children younger than 5 with 2 doses of OPV, regardless of immunization status

Surveillance

• Finding all cases of children with acute flaccid paralysis
• Stool sample analysis transport
• Isolating the virus in laboratories
• Mapping the virus/tracking outbreaks

Targeted “Mop-Up” Campaigns: Door-to-door campaigns in targeted areas of known polio infections or suspected areas

Enhancing Healthcare Team Outcomes

With an effective vaccine schedule, poliomyelitis is often a forgotten-about disease. Recognition that polio is still endemic in Pakistan and Afghanistan is important.[6] With the growing number of communities against vaccinations in developed countries, there is still much patient education to complete. Furthermore, the recognition and treatment of postpolio syndrome will need further discussion with improved testing capabilities in the future.

A comprehensive interprofessional approach to polio prevention and management is essential. This involves a team of clinicians, advanced practitioners, nurses, and pharmacists working collaboratively to deliver consistent messages to patients and their parents about vaccination schedules, the importance of hygiene, and the best practices for treating the disease when it occurs. 

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Greene SA, Ahmed J, Datta SD, Burns CC, Quddus A, Vertefeuille JF, Wassilak SGF. Progress Toward Polio Eradication - Worldwide, January 2017-March 2019. MMWR Morb Mortal Wkly Rep. 2019 May 24;68(20):458-462. [PMC free article: PMC6532951] [PubMed: 31120868]

2.

Arita M. Poliovirus Studies during the Endgame of the Polio Eradication Program. Jpn J Infect Dis. 2017 Jan 24;70(1):1-6. [PubMed: 27795480]

3.

Helfferich J, Knoester M, Van Leer-Buter CC, Neuteboom RF, Meiners LC, Niesters HG, Brouwer OF. Acute flaccid myelitis and enterovirus D68: lessons from the past and present. Eur J Pediatr. 2019 Sep;178(9):1305-1315. [PMC free article: PMC6694036] [PubMed: 31338675]

4.

Brown B, Oberste MS, Maher K, Pallansch MA. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J Virol. 2003 Aug;77(16):8973-84. [PMC free article: PMC167246] [PubMed: 12885914]

5.

Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014 Nov 01;210 Suppl 1(Suppl 1):S380-9. [PMC free article: PMC10424844] [PubMed: 25316859]

6.

O'Reilly KM, Lamoureux C, Molodecky NA, Lyons H, Grassly NC, Tallis G. An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia. BMC Infect Dis. 2017 May 26;17(1):367. [PMC free article: PMC5446690] [PubMed: 28549485]

7.

Al Awaidy ST, Khamis F. Wild Poliovirus Type 1 in Oman: A re-emerging threat that requires urgent, targeted and strategic preparedness. Sultan Qaboos Univ Med J. 2020 Feb;20(1):e1-e4. [PMC free article: PMC7065690] [PubMed: 32190363]

8.

Davlantes E, Greene SA, Tobolowsky FA, Biya O, Wiesen E, Abebe F, Weldetsadik MB, Eboh VA, Chisema MN, da Conceição Mário B, Tinuga F, Bobo PM, Chigodo CK, Sethy G, Hellström JM, Goundara AM, Burny ME, Mwale JC, Jorba J, Makua KS, Howard W, Seakamela L, Okiror S, Thompson A, Ali A, Samba D, Agbo C, Kabamba L, Kazoka A, Zomahoun DL, Manneh F, Abdelrahim K, Kamugisha C, Umar AS. Update on Wild Poliovirus Type 1 Outbreak - Southeastern Africa, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023 Apr 14;72(15):391-397. [PMC free article: PMC10121257] [PubMed: 37053125]

9.

Mehndiratta MM, Mehndiratta P, Pande R. Poliomyelitis: historical facts, epidemiology, and current challenges in eradication. Neurohospitalist. 2014 Oct;4(4):223-9. [PMC free article: PMC4212416] [PubMed: 25360208]

10.

Kidd D, Williams AJ, Howard RS. Poliomyelitis. Postgrad Med J. 1996 Nov;72(853):641-7. [PMC free article: PMC2398624] [PubMed: 8944203]

11.

Howard RS. Poliomyelitis and the postpolio syndrome. BMJ. 2005 Jun 04;330(7503):1314-8. [PMC free article: PMC558211] [PubMed: 15933355]

12.

Wiechers DO. Acute and latent effect of poliomyelitis on the motor unit as revealed by electromyography. Orthopedics. 1985 Jul;8(7):870-2. [PubMed: 3006005]

13.

Gonzalez H, Ottervald J, Nilsson KC, Sjögren N, Miliotis T, Von Bahr H, Khademi M, Eriksson B, Kjellström S, Vegvari A, Harris R, Marko-Varga G, Borg K, Nilsson J, Laurell T, Olsson T, Franzén B. Identification of novel candidate protein biomarkers for the post-polio syndrome - implications for diagnosis, neurodegeneration and neuroinflammation. J Proteomics. 2009 Jan 30;71(6):670-81. [PubMed: 19100873]

14.

Ragonese P, Fierro B, Salemi G, Randisi G, Buffa D, D'Amelio M, Aloisio A, Savettieri G. Prevalence and risk factors of post-polio syndrome in a cohort of polio survivors. J Neurol Sci. 2005 Sep 15;236(1-2):31-5. [PubMed: 16014307]

15.

McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol. 1988 Sep;128(3):615-28. [PubMed: 2843039]

16.

Freedman DO, Chen LH. Vaccines for International Travel. Mayo Clin Proc. 2019 Nov;94(11):2314-2339. [PubMed: 31685156]

17.

Fischer TK, Simmonds P, Harvala H. The importance of enterovirus surveillance in a post-polio world. Lancet Infect Dis. 2022 Jan;22(1):e35-e40. [PubMed: 34265258]

18.

Kawajiri S, Tani M, Noda K, Fujishima K, Hattori N, Okuma Y. Segmental zoster paresis of limbs: report of three cases and review of literature. Neurologist. 2007 Sep;13(5):313-7. [PubMed: 17848871]

19.

Chopra JS, Banerjee AK, Murthy JM, Pal SR. Paralytic rabies: a clinico-pathological study. Brain. 1980 Dec;103(4):789-802. [PubMed: 7437890]

20.

Bang H, Suh JH, Lee SY, Kim K, Yang EJ, Jung SH, Jang SN, Han SJ, Kim WH, Oh MG, Kim JH, Lee SG, Lim JY. Post-polio syndrome and risk factors in korean polio survivors: a baseline survey by telephone interview. Ann Rehabil Med. 2014 Oct;38(5):637-47. [PMC free article: PMC4221392] [PubMed: 25379493]

21.

Lo JK, Robinson LR. Postpolio syndrome and the late effects of poliomyelitis. Part 1. pathogenesis, biomechanical considerations, diagnosis, and investigations. Muscle Nerve. 2018 Dec;58(6):751-759. [PubMed: 29752819]

22.

Rekand T, Albrektsen G, Langeland N, Aarli JA. Risk of symptoms related to late effects of poliomyelitis. Acta Neurol Scand. 2000 Mar;101(3):153-8. [PubMed: 10705936]

23.

Chu ECP, Lam KKW. Post-poliomyelitis syndrome. Int Med Case Rep J. 2019;12:261-264. [PMC free article: PMC6690913] [PubMed: 31496835]

Disclosure: Jonathan Wolbert declares no relevant financial relationships with ineligible companies.

Disclosure: Michael Rajnik declares no relevant financial relationships with ineligible companies.

Disclosure: Karla Higginbotham declares no relevant financial relationships with ineligible companies.